G Genpact LTD Insider Trading

Genpact SVP Vashisht Riju sold 16,016 shares at $46.65; 2 prior same-ticker sales both well-timed at 90-day horizon

Vashisht Riju sold 16,016 shares at $46.65 on 2026-01-13, reducing his holdings by 14.4% and raising $747.1K. The current price of $46.52 is -16.2% from the 52-week high of $55.54, placing the stock in the lower half of its annual range. Notably, his prior 2 trades at Genpact (both August 2025 sales) were well-timed at the 90-day mark, with subsequent declines of -4.1% and -4.0% respectively, suggesting a consistent pattern of selling before downturns. With Genpact trading at a reasonable P/E of 14.54 and reporting $1.3B quarterly revenue with 6.5% annual growth, the company's fundamentals remain solid, but the insider's historical success at identifying local peaks warrants attention.

Dewan Sameer (SVP) sold 15,088 shares of Genpact at $46.65, reducing holdings by -28.6% to 37.7K shares.

SVP Dewan Sameer sold 15,088 shares at $46.65, a substantial reduction of -28.6% of his pre-transaction holdings from 52.8K to 37.7K shares. The sale occurred at a price -16.2% below the 52-week high of $55.54, and at a level -0.3% below the current price of $46.52. Across his prior open-market trades at Genpact, his two prior sells (2025-11-11 and 2025-08-28) produced mixed timing outcomes: the August 2025 sale was followed by a 90-day decline of -1.8%, while the November 2025 sale shows a 30-day gain of +6.0% with the 90-day measurement not yet available. The magnitude of this reduction in holdings warrants attention, though the stock trades at a moderate P/E of 14.54 with recent 90-day performance of +18.0%.

CFO Weiner sells 13,365 shares of Genpact (G) at $44.84; retains 148,026 shares post-sale

Chief Financial Officer Michael Hal Weiner sold 13,365 shares at $44.84 on 2025-11-14 for total value $599,286.60, reducing holdings by 8.3% to 148,026 shares. The current price of $43.74 is 21.2% below the 52-week high of $55.54, and the sale occurred when the stock was up 10.9% over 30 days but down 2.3% over 90 days. The company posted solid fundamentals with $1.3B quarterly revenue (+6.5% annual growth) and a P/E of 13.67, indicating the stock was not trading at a depressed valuation at the time of sale. The sale represents a routine, modest reduction in an executive's concentrated position while maintaining substantial remaining ownership.

SVP & Chief Legal Officer White Heather sold 51,093 shares for $2.3M across 3 transactions, reducing holdings by 50.3%

White Heather executed 3 separate sales totaling 51,093 shares for $2,335,206.74 over three days (November 11–13, 2025), at prices ranging from $44.02 to $45.74 and a blended average of $45.71. This sale reduced her holdings from 101,662 shares to 50,569 shares, a reduction of -50.3% of pre-transaction holdings. The current stock price of $45.05 is 18.9% below the 52-week high of $55.54; however, the stock has risen 13.0% over the past 30 days and 3.2% over 90 days from the time of filing. Across her cross-ticker history, her prior sell generated a -7.8% 30-day return and -10.9% 90-day return, and she achieved a 100.00% well-timed rate at the 90-day mark (meaning prior sells preceded stock declines). At Genpact specifically, her single prior sale in May 2023 also delivered negative 90-day returns of -10.9%, consistent with a pattern of selling before downturns. The company's fundamentals show $1.3B in revenue, $145.8M net income, 6.5% annual revenue growth, and a P/E of 14.08.

Genpact SVP Sameer Dewan sold 26,531 shares at $44.70 on 2025-11-11, retaining 62,617 shares post-sale.

Sameer Dewan, Senior Vice President, executed an open-market sale of 26,531 shares (29.8% reduction in holdings) at $44.70, lowering his stake from 89,148 to 62,617 shares. The sale occurred in a context where Genpact's stock is currently -18.9% from its 52-week high of $55.54 but has gained 13.0% over the past 30 days and 3.2% over 90 days. Across his cross-ticker trading history, Dewan has executed 1 prior sell with an average 30-day return of -6.2%, and his single prior trade at G (a sell on 2025-08-28) also posted a 30-day return of -6.2%, though the 90-day outcome remains unmeasurable. Genpact's fundamentals remain intact with $1.3B in latest-quarter revenue, $145.8M net income, and a P/E of 14.08, providing limited fundamental context for the sale rationale.

CHRO Piyush Mehta sells 76,902 shares of Genpact (G) for $3,274,487.16 in two transactions at $42.58

Mehta Piyush, Senior Vice President and CHRO, executed two separate open-market sales totaling 76,902 shares for $3,274,487.16 at a blended average price of $42.58. The sale reduced his holdings by 36.3%, from 211,782 shares to 134,880 shares post-transaction. His cross-ticker track record shows mixed timing: 8 prior sells averaged -0.4% 30-day return and -0.9% 90-day return, with a 37.50% well-timed rate. At Genpact specifically, his prior 5 sales have produced positive 90-day returns in 100% of measurable cases, indicating he has historically sold ahead of subsequent gains at this ticker. The stock currently trades at $42.11, only 0.11% below the transaction price, and is down 24.2% from its 52-week high of $55.54, suggesting the timing of this sale near recent lows differs from his prior Genpact sell pattern.

CEO Balkrishan sells 55,000 shares at $43.36–$43.39 for $2.4M, reducing stake by 15.7%

Kalra Balkrishan, President and CEO of Genpact, executed 2 separate sales totaling 55,000 shares for $2,384,850.00 at a blended average price of $43.36, reducing his post-transaction holdings to 295,246 shares from 350,246 shares. The sales occurred as the stock trades at $42.11, down 24.2% from its 52-week high of $55.54. Balkrishan's prior 2 sells at Genpact generated a 90-day return of -10.3% (March 2025) and +10.6% (December 2024), with 1 of 2 well-timed at the 90-day mark. This sale represents a meaningful reduction in executive exposure at a depressed valuation relative to recent highs, following a pattern of occasional equity reductions at this ticker.

SVP Dewan Sameer sold 20,078 shares of Genpact at $45.00; -18.4% from 52-week high.

Dewan Sameer, Senior Vice President of Genpact, sold 20,078 shares for $903,510.00, reducing his holdings by 18.4% from 109,226 to 89,148 shares. The sale occurred at $45.00 per share, approximately 18.4% below the 52-week high of $55.54. Genpact is a $7.9B market-cap company with solid fundamentals (6.5% annual revenue growth, P/E of 14.67, and latest quarter revenue of $1.3B). The stock has recovered 5.3% over the past 90 days and 2.6% over the past 30 days, suggesting recent price momentum. Without visibility into the executive's compensation structure, vesting schedules, or prior trading activity, the sale is most consistent with routine portfolio management by a senior executive retaining substantial ownership (89.1K shares post-transaction).

Genpact SVP Nanduru Anil sold 27,962 shares (28.0K) across 2 transactions for $1,254,053.00, reducing stake by -23.7% to 89,846 shares post-transaction.

Nanduru Anil, Senior Vice President at Genpact LTD, executed two separate sales on consecutive trading days (2025-08-21 and 2025-08-22), selling 18,218 shares at $44.50 and 9,744 shares at $45.50, for a combined $1,254,053.00 at a blended average price of $44.85. This represents a material reduction of -23.7% of his pre-transaction holdings (from 117,808 to 89,846 shares), totaling 27,962 shares. At the time of sale, the stock was trading near the current price of $45.45 and has historically traded in a 52-week range of $38.17–$55.54, positioning these sales near the middle of that band. The company's fundamentals remain stable with a P/E of 14.71, annual revenue growth of +6.5%, and quarterly revenue of $1,254,418,000.00. The scale and timing of this multi-transaction disposition merit observation given the significant reduction in the insider's proportional ownership stake.

SVP Riju sold 25,539 shares of Genpact (G) for $1,164,516.55 in 2 transactions on 2025-08-22

Vashisht Riju, Senior Vice President at Genpact, executed 2 separate sales totaling 25,539 shares for $1,164,516.55 at a blended average price of $45.60 on August 22, 2025. The sale represents a 17.3% reduction in his post-transaction holdings to 122,270 shares. The transaction occurred near the current price of $45.45, while the stock is -18.2% from its 52-week high of $55.54 and trades at a P/E of 14.71 with steady fundamentals (6.5% annual revenue growth, $132.7M net income). The sale is material in dollar terms but reflects a disciplined reduction of a substantial remaining position, with no prior activity pattern or scheduled plan flags visible in this filing.